单枚玻璃化复苏整倍体囊胚移植前的内膜准备:雌二醇治疗时长是否影响临床结局
回顾性队列研究纳入1439例接受自体冻存-only体外受精联合胚胎植入前遗传学检测、随后以雌激素联合孕激素准备内膜行冻存整倍体囊胚移植的患者。雌激素给药时长(平均17.5±2.9天,范围10-36天)对种植、临床妊娠、早期妊娠丢失及活产均无影响;每增加一天雌激素给药,分娩时孕周减少(β=-0.07±0.03周),但早产 odds 未受影响。作者结论认为雌二醇补充时长变异不影响冻存整倍体囊胚移植结局,雌激素给药时长与分娩孕周呈负相关但未转化为早产增加,需进一步研究内膜准备对胎盘-内膜界面的下游影响。
要点
- 雌激素给药时长对冻存整倍体囊胚移植的种植、临床妊娠、早期妊娠丢失及活产无影响。
- 每增加一天雌激素给药,分娩孕周减少(β=-0.07±0.03周),但早产 odds 未受影响。
- 雌激素暴露时长不影响婴儿出生体重(克)(β=-10.65±8.91)或低出生体重 odds。
核心结论
- 雌二醇补充时长变异不影响冻存整倍体囊胚移植结局。
- 雌激素给药时长与分娩孕周呈负相关,但未转化为早产增加。
- 作者认为需进一步研究内膜准备对胎盘-内膜界面的下游影响。
研究设计与样本
- 回顾性队列研究,共纳入1439例接受自体冻存-only体外受精联合胚胎植入前遗传学检测、随后以雌激素联合孕激素准备内膜行冻存整倍体囊胚移植的患者。
- 研究场所为私立学术生育中心。
- 干预:无。
主要发现
- 雌激素给药时长(平均17.5±2.9天,范围10-36天)对种植无影响(OR 0.99;95%CI 0.95-1.03)。
- 雌激素给药时长对临床妊娠无影响(OR 0.98;95%CI 0.94-1.01)。
- 雌激素给药时长对早期妊娠丢失无影响(OR 1.03;95%CI 0.95-1.12)。
- 雌激素给药时长对活产无影响(OR 0.99;95%CI 0.95-1.03)。
- 雌激素暴露时长不影响婴儿出生体重(克)(β=-10.65±8.91)或低出生体重 odds(OR 0.87;95%CI 0.68-1.13);每增加一天雌激素给药,分娩孕周减少(β=-0.07±0.03周),但早产 odds 未受影响(OR 1.05;95%CI 0.95-1.17)。
关键数值与推荐
- 主要结局为活产;次要结局包括种植、临床妊娠、早期妊娠丢失、活产、婴儿出生体重、低出生体重、婴儿分娩孕周及早产。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
- 作者在结论中提出需进一步研究内膜准备对胎盘-内膜界面的下游影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether the duration of estrogen administration before euploid embryo transfer affects clinical outcome. DESIGN: Retrospective cohort study. SETTING: Private, academic fertility center. PATIENT(S): Patients (n = 1,439) undergoing autologous freeze-only in vitro fertilization with preimplantation genetic testing (PGT) followed by endometrial preparation with estrogen and progesterone in a frozen, euploid blastocyst transfer cycle. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Primary outcome was live birth, and secondary outcomes included implantation, clinical pregnancy, early pregnancy loss, live birth, infant birthweight, low birth weight, infant gestational age at delivery, and preterm birth. RESULT(S): The duration of estrogen administration (mean: 17.5 ± 2.9 days; range: 10-36 days) before frozen embryo transfer did not impact implantation (odds ratio [OR] 0.99; 95% confidence interval [CI], 0.95-1.03), clinical pregnancy (OR 0.98; 95% CI, 0.94-1.01), early pregnancy loss (OR 1.03; 95% CI, 0.95-1.12), or live birth (OR 0.99; 95% CI, 0.95-1.03). The duration of estrogen exposure did not affect infant birthweight (in grams) (β= -10.65 ± 8.91) or the odds of low birth weight (OR 0.87; 95% CI, 0.68-1.13). For every additional day of estrogen administration, we observed a reduction in gestational age at delivery (in weeks) (β= -0.07 ± 0.03), but the odds of preterm delivery were not affected (OR 1.05; 95% CI, 0.95-1.17). CONCLUSION(S): Variation in the duration of estradiol supplementation before progesterone initiation does not impact frozen, euploid blastocyst transfer outcome. The duration of estrogen administration was inversely correlated with gestational age at delivery, but this did not translate into an increase in preterm delivery. Further studies are required on the downstream effects of endometrial preparation on the placental-endometrium interface.
引用
- Sekhon L, Feuerstein J, Pan S, et al. Endometrial preparation before the transfer of single, vitrified-warmed, euploid blastocysts: does the duration of estradiol treatment influence clinical outcome? Fertil Steril. 2019. PMID: 31029432. doi:10.1016/j.fertnstert.2019.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。